PT-141 is the only peptide that directly targets the brain's sexual desire pathways. Unlike treatments that address physical mechanics, PT-141 restores the neurological drive behind libido — for both men and women.
Most sexual health treatments — Viagra, Cialis, testosterone — address blood flow or hormone levels. PT-141 takes a different approach: it activates melanocortin receptors in the hypothalamus, the brain region that governs sexual motivation and desire. This makes it uniquely effective for patients whose issue is libido itself, not just physical function.
Sildenafil (Viagra) / Tadalafil (Cialis): Work by relaxing blood vessels and increasing blood flow. Effective for erectile mechanics but do nothing for desire or libido.
Testosterone Therapy: Improves overall drive and energy but works indirectly on sexual desire through systemic hormone restoration — takes weeks to months.
PT-141 (Bremelanotide): Directly activates melanocortin 3 and 4 receptors in the brain that drive sexual desire. Works within 45–60 minutes. Addresses libido at the neurological level — the root of desire — for both men and women.
A private 15-minute consultation with Dr. Paul to discuss your situation. No judgment, no awkwardness. This is a conversation we have every day.
We confirm you're a good candidate based on your health history. Lab work is not required for PT-141 in most cases — a clinical history is sufficient.
PT-141 is compounded by a licensed pharmacy and shipped directly to your door in discreet packaging. We provide injection instructions.
PT-141 is not a daily medication. It's administered via subcutaneous injection 45–60 minutes before sexual activity. Effects last 6–12 hours.
PT-141 (bremelanotide) is a melanocortin receptor agonist peptide — it activates MC3R and MC4R receptors in the hypothalamus, which directly drive sexual motivation and arousal. It's the only treatment that works on the brain's desire circuitry directly, rather than addressing blood flow or hormone levels alone.
Yes. Bremelanotide is FDA-approved under the brand name Vyleesi specifically for hypoactive sexual desire disorder (HSDD) in premenopausal women. At Juvenis Medical, we prescribe it as a compounded peptide — which allows for flexible dosing and significantly lower cost than the brand-name version.
Clinical trials showed statistically significant improvements in satisfying sexual events and desire scores compared to placebo. Most patients who are good candidates experience meaningful improvement. It works best when the underlying issue is desire and arousal rather than purely vascular or hormone-level driven.
The most common side effect is mild, temporary nausea — typically lasting 1–2 hours after injection. Facial flushing and mild headache are also reported. These effects are reduced by starting with lower doses and titrating up. Importantly, PT-141 does not cause the cardiovascular side effects associated with PDE5 inhibitors.
Yes. PT-141 is frequently combined with PDE5 inhibitors for men who need both central arousal stimulation and vascular support. It also pairs well with testosterone therapy. We'll advise on appropriate combination protocols based on your situation.
PT-141 is available via telehealth nationwide. The consultation is private, confidential, and judgment-free. Let's talk.
Book Free Private Consultation →